Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation Journal Article
| Authors: | Atanackovic, D.; Arfsten, J.; Cao, Y.; Gnjatic, S.; Schnieders, F.; Bartels, K.; Schilling, G.; Faltz, C.; Wolschke, C.; Dierlamm, J.; Ritter, G.; Eiermann, T.; Hossfeld, D. K.; Zander, A. R.; Jungbluth, A. A.; Old, L. J.; Bokemeyer, C.; Kroger, N. |
| Article Title: | Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation |
| Abstract: | Immunotherapies using cancer-testis (CT) antigens as targets represent a potentially useful treatment in patients with multiple myeloma (MM) who commonly show recurrent disease following chemotherapy. We analyzed the expression of 11 CT antigens in bone marrow samples from patients with MM (n = 55) and healthy donors (n = 32) using reverse transcriptase-polymerase chain reaction (RT-PCR). CT antigens were frequently expressed in MM with 56% (MAGEC2), 55% (MAGEA3), 35% (SSX1), 20% (SSX4, SSX5), 16% (SSX2), 15% (BAGE), 7% (NYESO-1), and 6% (ADAM2, LIPI) expressing the given antigen. Importantly, CT antigens were not expressed in healthy bone marrow. Analyzing patients with MM (n = 66) for antibody responses against MAGEA3, SSX2, and NY-ESO-1, we found strong antibody responses against CT antigens preferentially in patients who had received allogeneic stem cell transplantation (alloSCT). Antibody responses against NY-ESO-1 correlated with NY-ESO-1-specific CD4+ and CD8+ T-cell responses against peptide NY-ESO-151-62 and CD4+ responses against NY-ESO-1121-140 in 1 of these patients. These allogeneic immune responses were not detectable in pretransplantation samples and in the patients' stem cell donors, indicating that CT antigens might indeed represent natural targets for graft-versus-myeloma effects. Immune responses induced by alloSCT could be boosted by active CT antigen-specific immunotherapy, which might help to achieve long-lasting remissions in patients with MM. © 2007 by The American Society of Hematology. |
| Keywords: | adult; controlled study; human tissue; middle aged; transplantation, homologous; human cell; major clinical study; case-control studies; allogeneic stem cell transplantation; antigen expression; cd8+ t lymphocyte; t-lymphocytes; reverse transcription polymerase chain reaction; multiple myeloma; bone marrow; membrane proteins; hematopoietic stem cell transplantation; gene expression regulation; correlation analysis; immune response; immunotherapy; antigens, neoplasm; reverse transcriptase polymerase chain reaction; cancer testis antigen; ny eso 1 antigen; antibody response; cd4+ t lymphocyte; remission; immunity; antibodies, neoplasm; graft versus leukemia effect; graft vs tumor effect; t lymphocyte activation |
| Journal Title: | Blood |
| Volume: | 109 |
| Issue: | 3 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2007-02-01 |
| Start Page: | 1103 |
| End Page: | 1112 |
| Language: | English |
| DOI: | 10.1182/blood-2006-04-014480 |
| PUBMED: | 17023585 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 50" - "Export Date: 17 November 2011" - "CODEN: BLOOA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work